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INTRODUCTION
Patients with severe mental illness (SMI), 
including schizophrenia, bipolar affective 
disorder, and schizoaffective disorder or 
other non-organic psychoses, experience 
lower life expectancy than the general 
population.1–4 This is largely attributed to 
common physical disorders, particularly 
cardiovascular diseases (CVDs).2,3,5,6
Excess mortality linked to CVDs is 
attributed to several factors, including 
elevated risk factors such as smoking; 
side effects of pharmacological treatment; 
diagnostic overshadowing; and, suboptimal 
management of comorbid physical 
conditions.7–14 Previous studies have been 
unable to investigate associations for varying 
SMI-related characteristics as data on 
physical health and clinical management sit 
mainly within primary care, whereas mental 
health condition and management records 
are mainly stored in secondary care.
This study uses London borough 
population-based data from a linkage of 
primary and secondary mental healthcare 
records to: compare CVD prevalence, 
risk factor recording and treatment 
for established CVD, and primary care 
consultation frequency by SMI status; 
examine whether SMI characteristics are 
differentially associated with CVD prevalence 
and treatment; and assess the impact of 
adjustments for consultation frequency.
METHOD
Setting and data sources
Lambeth is a diverse borough in south east 
London, with a greater proportion of black 
Caribbean and black African residents but 
fewer South Asian residents than other 
areas,15 and is more deprived than England 
as a whole.16 Pseudonymised primary care 
data were extracted on 31 March 2013 from 
computerised medical records of all except 
one GP practice (n = 48) within Lambeth, as 
part of Lambeth DataNet (LDN) covering a 
population of 366 317 registered patients. 
This was a cross-sectional extract of 
LDN, but for some records (for example 
blood pressure [BP]), information on all 
measures recorded from 31 January 
2012 to 31 October 2013 were collected to 
determine whether Quality and Outcomes 
Framework (QOF)17 clinical targets had been 
met. Secondary care data came from the 
Case Register Interactive Search (CRIS),18 
an application allowing researchers access 
to pseudonymised electronic health record 
(EHR) data from the South London and 
Maudsley NHS Foundation Trust (SLaM). 
CRIS provides searchable access to 
de-identified text (unstructured data) from 
the clinical record.
Data linkage
Data were linked and stored by the Clinical 
Data Linkage Service (CDLS), which 
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provides a safe haven environment with 
strict governance arrangements. Data were 
linked using encrypted NHS numbers, 
which were subsequently removed and 
destroyed, fully anonymising the linked 
dataset.
Measures
Lambeth DataNet (LDN). Data were 
extracted on sex, year of birth, ethnic 
group, and 2011-defined lower super 
output area (LSOA). LSOA data were used 
to estimate deprivation on the basis of 
patient area of residence using the Index 
of Multiple Deprivation (IMD-2010) and 
a conversion to 2011 LSOA values. GP 
clinical register data (lists established 
and maintained by practices of patients 
identified with particular clinical outcomes 
for QOF purposes) were collected for heart 
failure (HF), coronary heart disease (CHD), 
hypertension (HYP), and stroke/transient 
ischaemic attack (STIA). Data were also 
collected on CVD risk factor recording, for 
example BP; clinical values and dates; and, 
mean number of primary care consultations 
(including GP, nurse, face-to-face, and 
telephone) between 2010 and 2013. A binary 
variable was created to distinguish median 
or below and above median annual number 
of consultations. 
Case Register Interactive Search (CRIS). 
Diagnostic codes for any primary or 
secondary diagnosis of schizophrenia, 
bipolar affective disorder, and schizoaffective 
disorder or other non-organic psychoses 
were extracted. An indicator of SMI severity 
was created, coding patients with SMI as 1 if 
they ever had a record of: an inpatient stay, 
being treated under the Mental Health Act, 
difficulty managing their physical health, 
or contact with Assertive Outreach, Crisis 
or A&E liaison team (or 0 if they had not 
been recorded with any of these). Similarly, 
an indicator of risk coded patients with 
SMI as 1 or 0 to indicate if they had ever 
been identified under the ‘violence and 
aggression’ subscale of risk assessment 
with a history of violence, non-compliance, 
or forensic history. Lastly, binary indicators 
of antipsychotic medication prescription 
were extracted; including binary indicators 
of atypical, typical, and depot injectable 
medication.
Statistical analyses
Pearson’s χ2 tests and logistic regression 
analyses were used to compare CVD 
prevalence, risk factor recording, QOF 
target achievement, and primary care 
consultation frequency by SMI status. Using 
How this fits in
Patients with severe mental illness (SMI) 
experience lower life expectancy than the 
general population. Suboptimal treatment 
of cardiovascular diseases has been 
identified as a potential contributory factor. 
This study found that patients with SMI in 
south east London are underprescribed 
beta blockers and angiotensin converting 
enzyme inhibitors/angiotensin receptor 
blockers as secondary prevention after 
coronary heart disease and heart failure. 
This may help clinicians to identify patients 
at greatest risk of suboptimal treatment.
Table 1. Sociodemographic characteristics and CVD prevalence by 
severe mental illness (SMI) status 
  Non-SMI (N  = 270 669), n (%) SMI (N  = 4056), n (%) P-value
Sexa   <0.001b
 Female 137 353 (50.8) 1797 (44.3) 
 Male 133 315 (49.3) 2259 (55.7) 
Age group, years   <0.001b
 16–24 32 776 (12.1) 162 (4.0)
 25–34 88 062 (32.5) 678 (32.5)
 35–44 59 279 (21.9) 907 (22.4)
 45–54 42 839 (15.8) 1095 (27.0)
 55–64 23 734 (8.8) 624 (15.4)
 65–74 14 035 (5.2) 347 (8.6)
 ≥75 9944 (3.7) 243 (6.0)
Ethnic group   <0.001b
 British/mixed 78 332 (35.0) 1124 (31.6)
 Irish 5253 (2.4) 104 (2.9)
 Indian/Pakistani/Bangladeshi/mixed 16 042 (7.2) 219 (6.2)
 Caribbean/mixed  21 401 (9.6) 840 (23.7)
 African/mixed  27 286 (12.2) 545 (15.3)
 Chinese/other 10 871 (4.9) 90 (2.5)
 Other white 54 080 (24.2) 373 (10.5)
 Other black 6262 (2.8) 188 (5.3)
 Other mixed  4254 (1.9) 69 (1.9)
Deprivation quintile    <0.001b
 1 Most deprived 47 162 (18.1) 1004 (25.0)
 2 54 656 (21.0) 918 (22.9)
 3 54 342 (20.9) 836 (20.8)
 4 57 149 (22.0) 713 (17.8)
 5 Least deprived 47 054 (18.1) 543 (13.5)
Consultations   
 Mean (SD) 4.7 (4.3) 9.4 (8.0)
 Median/below  123 501 (53.1) 813 (20.9) <0.001b
 Above median 109 286 (47.0) 3074 (79.1)
Cardiovascular diseases   
 Hypertension 28 010 (10.4) 762 (18.8) <0.001b
 Coronary heart disease 4109 (1.5) 97 (2.4) <0.001b
 Heart failure 1259 (0.5) 45 (1.1) <0.001b
 Stroke/transient ischaemic attack 2544 (0.9) 100 (2.5) <0.001b
SD = standard deviation. SMI = severe mental illness. Patients with SMI are those known to both primary and 
secondary care, patients without SMI are those known only to primary care and not registered with a SMI. 
‘Consultations’ refers to mean number of GP and nurse telephone, face-to-face and home primary care 
consultations per calendar year between 2010 and 2013. a One patient recorded as sex ‘unknown’. bP <0.001.
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linked data, comparisons by SMI status in 
CVD prevalence and prescribing were then 
examined by individual SMI characteristics. 
Logistic regression analyses were used to 
assess whether any differences in CVD 
prevalence or prescribing could be accounted 
for by adjustment for sociodemographic 
characteristics and consultation frequency. 
P-values, unadjusted and adjusted odds 
ratios (OR), and 95% confidence intervals 
(CI) are shown. The large number of 
statistical tests conducted meant that an 
a level of P<0.01 was used to determine 
statistical significance. All analyses were 
conducted using Stata (version 12).
RESULTS
Data were obtained for LDN patients aged 
≥16 years (n = 295 301); of these, 8.1% 
(n = 23 919) were linked to secondary 
mental healthcare records. Among those 
with linked records, n = 4056 (16.9%) were 
recorded with SMI by their GP in LDN. 
Analyses compared those with recorded 
SMI in primary care with linked secondary 
care records (n = 4056) to those not 
recorded with SMI in primary care or linked 
to secondary care (n = 270 669).
Sociodemographics, CVD prevalence, and 
consultation frequency among patients 
with and without SMI
SMI status was associated with sex, age, 
ethnic group, deprivation, consultation 
frequency, and greater prevalence of CVDs 
(Table 1). In patients with an established 
CVD (data not shown) there were no longer 
associations between SMI status and sex, 
nor age among patients with CHD or STIA. 
SMI status was only associated with ethnic 
group and GP consultation rate among 
patients with HYP, and SMI status was no 
longer associated with deprivation among 
patients with any CVD condition.
Sociodemographic characteristics of SMI 
subgroups
The SMI characteristics extracted from 
secondary care data are shown in Table 2. 
Adjusting for all sociodemographic 
characteristics simultaneously (data 
not shown), being black African, black 
Caribbean, other black, and of a younger age 
were associated with indicators of risk and 
severity, and with receiving depot injectable 
antipsychotic medication; male sex was also 
associated with risk. Being black Caribbean 
and older was associated with receipt of 
typical antipsychotics, whereas younger age 
and being black African was associated with 
receipt of atypical antipsychotics. Relative 
to those with a diagnosis of schizophrenia, 
those diagnosed with bipolar disorder were 
younger, more likely to be identified as 
British/mixed British, female, and to consult 
primary care more frequently (P = 0.01). 
Those diagnosed with schizoaffective 
disorder/other non-organic psychoses were 
younger, more likely to be female, and to 
consult primary care less frequently relative 
to patients with schizophrenia  (except 
where indicated, all P-values <0.001).
CVD risk factor recording and QOF target 
achievement
CVD risk factor recording (for example 
BP) was, in general, high for patients with 
and without SMI (Table 3). Among those 
with established CVDs, patients with SMI 
were more likely to have a record of their 
alcohol intake. Among patients with HYP, 
SMI status was also associated with greater 
recording of body mass index and glycated 
haemoglobin levels. Patients with SMI 
with CHD were less likely to have a BP 
record, whereas those with STIA were less 
likely to have a record of BP and smoking 
status. CVD risk assessment (for example 
Framingham risk score) was significantly 
less common among patients with SMI. 
Despite significantly higher prevalence of 
CVDs in the SMI group overall, there was 
little or no difference in the prevalence of 
comorbid CVDs or diabetes by SMI status 
among those with established CVDs. 
Among patients with HYP, diabetes was 
significantly more common among patients 
with SMI than without. For most QOF 
targets, there was no significant difference 
between patients with SMI and patients 
without SMI. For patients with SMI as well 
as HF and CHD, a significant shortfall was 
observed in prescribing with ACE inhibitors 
or angiotensin receptor blockers (ACEIs/
ARBs) and beta blockers.
Regression analyses of QOF target 
achievement
Regression analyses (Table 4) focused 
on differences in CVD prescribing by SMI 
status as these differences have previously 
been identified as a potential contributor 
to excess cardiovascular mortality 
among patients with SMI,12 and were 
the key differences identified in Table 3. 
Associations between SMI status and beta 
blocker and ACEI/ARB medication among 
patients with HF remained after accounting 
for both sociodemographic characteristics 
and consultation rates. Among patients 
with CHD, the association between SMI 
status and beta blocker prescription was 
accounted for by ethnic group but the 
shortfall in ACEI/ARB prescribing among 
Table 2. Indicators of severity 
and risk identified from 
secondary care data among 
patients with severe mental 
illness
 N  = 4056,  
 n (%)
Diagnosis 
  Schizophrenia 1721 (53.6)
  Bipolar affective disorder 716 (22.3)
  Other non-organic psychoses 773 (24.1)
Indicator of severity, ever: 2147 (53.0)
  Treated under Mental Health Act 1416 (34.9)
  Inpatient 1927 (47.5)
  Seen by crisis team 23 (0.6)
  Seen by assertive outreach 11 (0.3)
  A&E outpatient episode 445 (11.0)
  Difficulty managing physical health 676 (16.7)
Indicator of risk, ever: 1751 (43.0)
  History of non-compliance 1296 (32.0)
  History of violence 1171 (28.9)
  Forensic history 620 (15.3) 
Antipsychotics, ever: 
  Depot injectable 1112 (32.3)
  Atypical 3255 (94.5)
  Typical  1506 (43.7)
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CHD patients with SMI remained after 
adjustments.
For analyses examining SMI-subgroups 
associated with beta blocker and ACEI/
ARB prescribing, CHD and HF were 
combined because of small numbers (Table 
5). After adjustments, prescribing of beta 
blocker and ACEI/ARB medication among 
patients with CHD or HF combined was 
significantly lower for patients with SMI 
overall (OR 0.48 and 0.42, respectively); and 
was particularly reduced for patients ever 
prescribed depot injectable antipsychotic 
medication (OR 0.22 and 0.32, respectively), 
those with any indicator of risk (OR 0.25 
and 0.22, respectively), those diagnosed 
with schizophrenia (OR 0.38 and 0.27, 
respectively), and those with any indicator of 
SMI severity (OR 0.39 and 0.31, respectively).
DISCUSSION
Summary
Elevated rates of CVDs were found among 
patients with SMI; however, there may 
be underrecording of CVD comorbidities 
among patients with SMI and with 
established CVDs. Risk factor recording 
was high, although significant differences 
by SMI status were identified. Overall, QOF 
target achievement was not impaired in 
patients with SMI but significant consistent 
associations were found between SMI 
status and reduced prescribing of ACEI/ARB 
and beta blocker medication as secondary 
prevention of CHD and HF. Patients with 
SMI and with schizophrenia, those identified 
with any indicator of risk or illness severity, 
and those ever prescribed depot injectable 
antipsychotics were least likely to be 
prescribed ACEI/ARBs and beta blockers.
Strengths and limitations
This study makes use of a population-based 
data linkage between primary and secondary 
care records. It was possible to identify 
patient and illness-related characteristics 
associated with recording and treatment 
of CVDs and to highlight issues warranting 
further investigation that may best target 
disparities and reduce inequalities in 
physical comorbidity and mortality. 
The main limitation pertains to the 
generalisability to other geographical areas; 
however, the present findings are in line with 
evidence from national and international 
research, and it is believed that this study 
is proof of principle of the utility of data 
linkage, which could be used elsewhere 
to corroborate the findings. Although the 
analyses focus on incentivised QOF targets, 
it is possible that discrepancies in non-QOF 
targets may differ.
Comparison with existing literature
Although patients with SMI were more 
likely to be recorded with CVDs overall, 
little evidence was found for elevated rates 
of CVD comorbid conditions among those 
with established CVDs. Previous research 
has found no difference in the pattern of 
physical health co- and multimorbidities by 
SMI status and lower than expected rates of 
certain CVDs among patients with SMI given 
higher CVD-related mortality.3,19,20,21 
One of several explanations suggested 
is that this may be linked to less frequent 
GP consultations20,21; however, in this study, 
elevated consultation rates are reported 
among patients with SMI overall, and among 
patients with SMI and with established CVD, 
in line with previous findings.22 Patients with 
SMI were less likely to have a CVD risk 
assessment, and although such tools may 
not be as accurate for the SMI population,23,24 
it is unclear whether this concern or other 
factors accounted for this observation.
Lower than expected differences were 
found in the proportion of black Caribbean 
patients with SMI among those with CHD 
and STIA. This suggests that either SMI 
status does not confer an excess risk of 
these outcomes or that CHD and STIA 
is less frequently recorded among black 
Caribbean patients with SMI; for example, 
Table 4. Differences in QOF CVD prescribing targetsa by serious mental 
illness status adjusted for sociodemographic characteristics and 
primary care consultation frequency
   Adjusted for Additionally adjusted 
 Reference Unadjusted OR sociodemographics for consultation 
 (non-SMI) (95% CI) ORb (95% CI) rate ORc (95% CI)
Beta blocker
 After CHD 1.00 0.62 (0.41 to 0.93)d 0.68 (0.44 to 1.05) 0.66 (0.42 to 1.01)
 After HF 1.00 0.29 (0.16 to 0.53)f 0.29 (0.15 to 0.55)f 0.27 (0.14 to 0.52)f
ACEI/ARB    
 After CHD  1.00 0.59 (0.36 to 0.97)d 0.55 (0.33 to 0.94)d 0.47 (0.27 to 0.80)e
 After HF 1.00 0.33 (0.18 to 0.61)f 0.34 (0.18 to 0.66)f 0.31 (0.16 to 0.60)f
Antiplatelet/anticoagulant    
 After CHD 1.00 0.95 (0.54 to 1.65) 1.04 (0.57 to 1.89) 0.94 (0.51 to 1.73)
 After STIA 1.00 1.04 (0.68 to 1.60) 0.99 (0.62 to 1.59) 1.04 (0.64 to 1.69)
Statin     
 After CHD 1.00 0.76 (0.45 to 1.28) 0.78 (0.45 to 1.36) 0.70 (0.40 to 1.23)
Quadruple therapy g    
 After CHD 1.00 0.65 (0.40 to 1.06) 0.62 (0.37 to 1.04) 0.28 (0.34 to 0.98)d
ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. CHD = coronary heart disease. 
CVD = cardiovascular disease. HF = heart failure. OR = odds ratio. QOF = Quality and Outcomes Framework.  
SMI = severe mental illness. STIA = stroke/ transient ischaemic attack. aRefers to QOF guidelines 2012/13.17 bAdjusted 
for age (continuous), sex, ethnic group, and borough-level deprivation. cAdditionally adjusted for mean annual 
number of primary consultations. dP <0.05. eP <0.01. fP <0.001. gQuadruple therapy indicated in patients with history of 
myocardial infarction and includes statin, antiplatelet/anticoagulant, beta blocker, and ACEI/ARB medication. 
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because of excess mortality. In line with 
previous findings,7,14,21,25 this study found 
evidence for reduced prescription of ACEI/
ARB and beta blocker medications for CVD 
secondary prevention. Underprescribing in 
CVDs has been linked previously with excess 
mortality among patients with SMI7,12,21,25,26 
and therefore may contribute to disparities 
in life expectancies. Reduced ACEI/ARB 
prescribing in CHD among patients with 
SMI could partly reflect differences in the 
effectiveness of these drugs as hypotensive 
agents among black Caribbean and black 
African patients.27 National Institute for 
Health and Care Excellence (NICE) HYP 
guidelines28 indicate prescribing of ARBs 
rather than ACEIs among black patients; 
however, the associations remained after 
adjustments for ethnic group and were 
robust when ACEI and ARB prescriptions 
were analysed separately. Reduced 
prescribing is also unlikely to be linked 
to reduced attendance at primary care as 
greater consultation frequency was found 
among patients with SMI, and adjustments 
strengthened negative associations with 
prescribing.
There may, however, be reluctance to 
prescribe certain CVD medications because 
of concerns about adherence. Adherence 
may be lower for drugs where the dose 
has to be up-titrated to maximally tolerated 
doses as for beta blockers and ACEI/ARBs; 
these medications require monitoring, and 
thus adherence to a monitoring regimen 
to assess for side-effects. Monitoring 
also involves regular blood tests; such 
a commitment may be perceived as too 
demanding for GPs assessing patients 
with SMI, and/or patients with SMI may 
be less willing to commit themselves to 
such monitoring. However, a recent US 
study assessing adherence in patients 
with and without schizophrenia found no 
evidence for reduced adherence to ACEI/
ARB medication.29 One reason previously 
suggested for reluctance to prescribe 
certain cardiovascular medications is the 
potential for harm in overdose.14,21 Although 
research does not support an association 
between cardiovascular medication and 
excess suicide,30,31 practitioners could 
conceivably have concerns around correct 
adherence among patients with SMI, for 
example, leading to accidental overdose.
Further quantitative and qualitative 
work may usefully further explore these 
explanations. Qualitative evidence suggests 
that primary care physicians may view 
patients with SMI as harder to manage,31,32 
and be less willing to intervene when 
cardiovascular risk factors are identified.33 
Further, there may be reluctance among 
patients with SMI to accept prescriptions 
because of mistrust or lack of adequate 
communication between physician 
and patient.34 For patients with greater 
illness severity, the role of secondary 
care physicians may be more pertinent in 
managing physical health.
Lastly, QOF exception rates (for 
example, because of informed dissent 
or treatment unsuitability) are higher in 
patients with SMI,35,36 potentially inflating 
QOF achievement. The present analyses 
did not exclude exception reported patients, 
however, so the reported achievement rates 
were not influenced by exception reporting 
among patients with SMI.
Beta blocker and ACEI/ARB prescription 
was reduced in patients with SMI with 
CHD or HF overall, but the reduction was 
greatest in patients with SMI identified with 
any indicator of risk, prescription of depot 
injectable antipsychotics, schizophrenia 
diagnosis, and any indicator of SMI severity. To 
the authors’ knowledge, these associations 
have not been previously investigated; 
however, Laursen et al 25 reported that rates 
of ‘unnatural’ deaths were elevated among 
patients with SMI who were not prescribed 
cardiovascular medication, also indicating 
an association with illness severity. The 
subgroups identified as most at risk of 
underprescribing may be those most likely 
to be seen as the ‘hardest to treat’ by GPs 
and those least likely to commit to the 
monitoring and follow-up as implied before. 
Further qualitative work should explore 
these associations among clinicians and 
patients who have been identified as at risk 
of underprescribing.
Implications for practice
These findings deepen the understanding 
of disparities in morbidity and health care 
among individuals with SMI and help to 
build possible explanations for these 
discrepancies by identifying characteristics 
of patients with SMI associated with the 
lowest likelihood of optimal treatment. The 
results underline the value of closer working 
between primary and secondary care in 
improving outcomes for patients with SMI. 
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